* If you want to update the article please login/register
Several disorders were attributed to erectile dysfunction, but there were no studies on erectile dysfunction in cirrhotic patients. Method: A cross-sectional research was conducted on 200 patients with liver cirrhosis who were divided into three groups according to Child score and erectile dysfunction. Results showed that the 80% prevalence of erectile dysfunction in the cirrhotic patient was 80%. The erectile dysfunction worsens with the liver disease's progression, and 20% of the cirrhotic patients had penile venous leakage that was 28. 6% in advance liver cirrhosis.
Source link: https://doi.org/10.21203/rs.3.rs-2464624/v1
Objectives People with cirrhosis are encouraged to participate in shared decision-making with their doctors, but studies show that doctors limit the amount of information that can be shared. In this report, we investigate the presence of medical power in clinical encounters in 2015 from a patient perspective and a reminder of healthcare interactions. Methods Qualitiative semi-structured interviews were conducted in ten people with cirrhosis attending a tertiary liver transplant center in southern England. Patients' perspectives of their doctor visits include: presenting a positive image to doctors, avoiding confrontation with doctors, and remaining fearless in the face of doctors' knowledge are among the key findings of doctors' medical education. People with cirrhosis are unable to articulate or contest their decisions regarding their care and treatment, and they may be concerned about the risks.
Source link: https://doi.org/10.1177/17423953211058422
Background: We examine the number of children with compensated cirrhosis who experience decompensation in Ontario, Canada, over the past two decades. The analysis of decompensation, type of decompensation, and the incidence of liver transplantation after decompensation were determined. Results: A total of n = 2,755 children with compensated cirrhosis were included, and 9% experienced decompensation over a median follow-up of 7 years were included. Decompensation-prone children were both younger and female. 199/2755 of children with cirrhosis received liver transplantation, of which 128/199 occurred after a decompensation function. Conclusion: We present the first study to determine decompensation, type, and rate of liver transplantation after decompensation in pediatric cirrhosis at the population level. To improve the care of children with liver disease, early detection of liver disease, early diagnosis of liver disease, early diagnosis of specific diseases, early intervention of targeted therapies, as well as identification of children at risk of becoming decompensated are all crucial.
Source link: https://doi.org/10.3138/canlivj-2022-0031
AbstractIntroduction: Liver cirrhosis is a degenerative liver disease caused by hepatitis B and C. Abstract: Liver cirrhosis is a degenerative liver disease that causes no significant differences in clinical and laboratory measurements between patients with liver cirrhosis caused by hepatitis B and C. The majority of cirrhosis patients were males over 40 years old, according to the results, 112 patients in this study had liver cirrhosis caused by hepatitis B and C. Conclusion: There was no significant difference between patients with liver cirrhosis caused by hepatitis B and C in comparison to hepatitis B and C.
Source link: https://doi.org/10.20473/juxta.v14i12023.30-35
At the same time, mortality from liver cirrhosis in the age group of 20 to 40 years outnumbers coronary heart disease at the same time. The classic signs of cirrhosis leave no doubt in the diagnosis; however, a thorough history and active detection of risk factors at the point of the latent course of the disease can avoid numerous hospitalizations and minimize the number of hospitalizations.
Source link: https://doi.org/10.33667/2078-5631-2022-35-14-18
In patients with hepatitis B-related cirrhosis receiving antiviral therapy, this research was determined that there was no relationship between probiotics and hepatocellular carcinoma. Project Description This retrospective review included 1267 patients with HBC treated with entecavir or tenofovir between January 2013 and December 2017. HCC risks were estimated between two groups of 449 probiotic users and 818 non-probiotic users. The prevalence of HCC in the probiotic users was much lower than that in the nonusers after PSM. Conclusion Adjuvant probiotic therapy may reduce the risk of HCC in patients receiving antiviral drugs for HBC.
Source link: https://doi.org/10.3389/fcimb.2022.1104399
The new study is designed to determine nitric oxide levels and a few other biochemical measurements in individuals with hepatic Cirrhosis disease. Results: The study group's serum nitric oxide levels were much higher than those of the control group's control group's. Conclusions: The rise of Nitric oxide concentrations may be a potential diagnostic marker of liver cirrhosis.
Source link: https://doi.org/10.22317/imj.v6i4.1187
Increased liver inflammation, as shown by higher serum alanine aminotransferase, was correlated with an elevated risk of hepatitis C virus cirrhosis in a previous analysis of patients with hepatitis C virus cirrhosis cirrhosis. Several agents have been suggested to have chemopreventive activity against the outbreak of HCC in chronic HCV-associated liver disease, including herbal drugs such as Stronger-Neophagen C and Sho-saiko-to. We hypothesized that lowering of liver inflammation, as seen by decreases in serum ALT, might reduce HCC incidence in patients with HCV-LC. In patients with early-stage HCV-LC, the preventive effects of UDCA on HCC was investigated in this research. The patients were followed up for more than five years and then analyzed into two groups: 56 UDCA members and 46 UDCA nonusers. The mean u00b1 SD dose administered in group A was 473. 7 u00b1 mg/d, which was 183. 0 mg/d. Compared to the 5-year study period, the average duration of UDCA administration in group A was 37. 3 months u00b1 15. 9 months. HCC in group A was 17. 9% in 5-years, which was significantly smaller than that in group B. In both the UDCA and non-UDCA groups, the herbal medications were used were similar in terms of dosage and treatment duration. Interestingly, since the serum ALT trends remained relatively stable in both groups, the chemopreventive effects of UDCA was not accompanied by larger declines in ALT as compared to those with the UDCA nonusers.
Source link: https://doi.org/10.1158/1055-9918.104.22.168
Following SVR achievement, the aim was to determine the importance of the portal venous blood flow and portosystemic shunts in patients with decompensated cirrhosis due to HCV infection. Methods : In 27 patients undergoing and after sofosbuvir/velpatasvir therapy, portal hypertension-related events and liver function were examined. Serum albumin level risen from 2. 9 at baseline to 3. 5 at 12 weeks after EOT, with liver volumes decreasing from 1,260 to 1,150. Portal venous blood flow, liver volume, serum albumin, and bilirubin levels at baseline were all associated with serum albumin levels at 12 weeks after EOT, according to a multi-line regression model. The initial portal venous blood flow and liver function were predicted of liver function after SVR, according to the size of portosystemic shunts, which was predicted for the portal hypertension-related event occurrence in patients with decompensated cirrhosis caused by HCV.
Source link: https://doi.org/10.21203/rs.3.rs-2423520/v1
Diabetes mellitus can be present in many different ways. Several studies have found the correlation between Diabetes mellitus and liver cirrhosis. Aim: To determine the prevalence of diabetes mellitus in liver cirrhosis patients at tertiary care hospital Methodology: Our research was based on a descriptive Cross-Sectional Study, which was conducted in Peshawar, Germany, from 08-11-2021 to 2022, the first year in our institution. 20 patients with liver cirrhosis were in our study, so the incidence of diabetes mellitus in liver cirrhosis patients was high. Conclusion: Our study found that the incidence of diabetes mellitus in patients with liver cirrhosis is high.
Source link: https://doi.org/10.53350/pjmhs20221612147
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions